NIAID-funded study traced evolution of Malaria drug resistance in East Africa
On Aug. 24, 2023, NIAID reported that emerging resistance to common malaria treatments in Uganda could be connected…
On Aug. 24, 2023, NIAID reported that emerging resistance to common malaria treatments in Uganda could be connected…
On Aug. 11, 2023, a study funded by the National Institute of Allergy and Infectious Diseases (NIAID) reported…
On Aug. 7, 2023, the United Kingdom Health and Security Agency announced the Vaccine Development and Evaluation Centre…
On Aug. 7, 2023, a National Institute of Health supported study found that in 2021, an estimated 2.5…
On Jan. 25, 2023, it was reported that adults living in rural areas of the United States have…
On Nov. 18, 2022, Pfizer and BioNTech announced results from an analysis examining the immune response induced by…
On Jul. 28, 2022, AlphaFold, in partnership with EMBL’s European Bioinformatics Institute (EMBL-EBI), announced they we’re releasing predicted…
On Jun. 30 2022, Pfizer announced the submission of a New Drug Application (NDA) to the U.S. Food…
Play the COVID-19 Wheel of Fortune and see how lucky you are! You have two wheels to choose…
On Jun. 2, 2022, the National Institutes of Health reported that the Age-Related Eye Disease Studies (AREDS and…
On Apr. 1, 2022, Merck and Ridgeback Biotherapeutics announced that data evaluating LAGEVRIO(molnupiravir), an investigational oral antiviral COVID-19…
On Mar. 21, 2022, in support of the Cancer Moonshot goal of fostering data sharing in cancer research,…
On Feb. 2, 2022, President Biden announced a reignition of the Cancer Moonshot, that highlighted new goals: to…
On Jan. 28, 2022, Merck and Ridgeback Biotherapeutics announced data from six preclinical studies demonstrating that molnupiravir, an…
On Jan. 18, 2022, Merck and Ridgeback Biotherapeutics announced the signing of a long-term supply agreement with the…
On Dec. 23, 2021, Merck and Ridgeback Biotherapeutics announced that the U.S. FDA had granted Emergency Use Authorization…
On Dec. 22, 2021, Gilead Sciences announced full results from a Phase 3 investigational study evaluating the efficacy…
The COVID-19 Roller Coaster is a wild ride, strap yourself in and hold on… Cast of Characters: Senator…
On Oct. 26, 2021, BioNTech announce that the Company planned to initiate the construction of the first state-of-the-art…
On Oct. 12, 2021, National Resilience announced a strategic collaboration with Children’s Hospital of Philadelphia (CHOP) to implement…
A tomb illustration in Memphis, Egypt, depictded a patient being bled from the foot and neck. Though the…
Around 600 BCE, Chinese healers created the first antibiotic – moldy soybean curds – to treat boils.
On Jul. 26, 2021, the American Medical Association (AMA) call for all health care and long-term care employers…
Planning a Summer vacation? Where to go? How about going to one of those large events with tens…
On Jun. 16, 2021, the University of Oxford announced the Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial demonstrated…
COVID-19 and it’s naysayers are attacking Science and Reason. The defenders must suffer the slings and arrows from…
On Apr. 14, 2021, the Mayo Clinic announced a new technology platform initiative to deliver the next generation…
On Mar. 2, 2021, Merck announced multiple agreements to support efforts to expand manufacturing capacity and supply of…
On Dec. 4, 2020, Novo Nordisk announced that the FDA approved an updated label for Saxenda (liraglutide) injection…
On Nov. 3, 2020, Medigen Vaccine Biologics (MVC) and the National Institute of Hygiene and Epidemiology (NIHE), a…